Evidence map›Paper›PMID 41418783›Full record

ArticleStem cell reports2026

High resolution multi-scale profiling of embryonic germ cell-like cell derivation reveals pluripotent state transitions in humans.

Sarah Stucchi, Lessly P Sepulveda-Rincon, Camille Dion, Gaja Matassa, Alessia Valenti, Cristina Cheroni, Alessandro Vitriolo, Filippo Prazzoli, George Young, Marco Tullio Rigoli and 8 more

Abstract read
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sarah StucchiHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Lessly P Sepulveda-RinconMRC Laboratory of Medical Sciences (LMS), London, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK.
Camille DionMRC Laboratory of Medical Sciences (LMS), London, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK.
Gaja MatassaHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Alessia ValentiHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Cristina CheroniHuman Technopole, Milan, Italy.
Alessandro VitrioloHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Filippo PrazzoliHuman Technopole, Milan, Italy.
George YoungMRC Laboratory of Medical Sciences (LMS), London, UK.
Marco Tullio RigoliHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Riccardo NagniHuman Technopole, Milan, Italy.
Martina CipriettiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Benedetta MudaHuman Technopole, Milan, Italy; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Zoe HeckhausenMRC Laboratory of Medical Sciences (LMS), London, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK.
Petra HajkovaMRC Laboratory of Medical Sciences (LMS), London, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK.
Nicolò CaporaleHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: nicolo.caporale@unimi.it.
Giuseppe TestaHuman Technopole, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: giuseppe.testa@fht.org.
Harry G LeitchMRC Laboratory of Medical Sciences (LMS), London, UK; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK. Electronic address: harry.leitch@ucl.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primordial germ cells (PGCs) are the embryonic precursors of the gametes. In rodents, PGCs readily form self-renewing embryonic germ cell (EGC) lines in vitro. Although human PGCs undergo a similar conversion during germ cell tumorigenesis, no comparable in vitro system has yet been established in humans. Here we report that hPGC-like cells (hPGCLCs) undergo conversion to human EGC-like cells (hEGCLCs) using the inductive signals previously identified in mice. This feeder-free culture system allows efficient derivation of hEGCLCs that are transcriptionally similar to human induced pluripotent stem cells and can give rise to hPGCLCs once more demonstrating the interconvertibility of pluripotent states. This is also evident at the chromatin level, as the initial DNA demethylation that occurs in hPGCLCs is reversed in hEGCLCs. This new in vitro model provides a highly tractable system to study human pluripotent and early developmental transitions, including those driving germ cell tumorigenesis and epigenetic inheritance.

Indexed as

Embryonic Germ CellsPluripotent Stem CellsAnimalsCell DifferentiationChromatinDNA MethylationEpigenesis, GeneticGene Expression ProfilingHumansInduced Pluripotent Stem CellsMiceChromatinDNA methylationembryonic germ cellsepigenetic reprogramminggerm cell tumormulti-omicspluripotencyprimordial germ cellssingle-cell transcriptomics

Identifiers

PMID41418783
PMCPMC12925952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.